Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD5055 + nintedanib
- Development stage
- Discontinued
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AZD5055 + nintedanib is a combination of **AZD5055**, an investigational oral small molecule **Porcupine (PORCN) inhibitor** targeting the Wnt signaling pathway, and **nintedanib**, an approved oral **tyrosine kinase inhibitor** with antifibrotic and antiangiogenic activity. AZD5055 is under development for **idiopathic pulmonary fibrosis (IPF)** and other interstitial lung diseases (ILDs), with evidence of target engagement in skin and experimental models supporting its activity in lung tissue. Nintedanib is approved for IPF and other progressive fibrosing ILDs. The combination is being evaluated in clinical trials for effects on pharmacokinetics, safety, and tolerability in healthy volunteers, but no major pharmacokinetic interactions have been observed when co-administered[1][3][5].
- Other names
- AZD5055 + nintedanib
02
Targets
FGFR (Fibroblast growth factor receptor)FLT3 (Fms related receptor tyrosine kinase 3)LCK (Proto-oncogene tyrosine-protein kinase Lck)PDGFR (PDGFR family)PORCN (Porcupine protein)VEGFR (VEGFR family)
Beyond the preview
Go deeper on AZD5055 + nintedanib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD5055 + nintedanib.